The combination of lenvatinib and pembrolizumab has shown updated long-term efficacy and safety in patients with pretreated, advanced thymic tumors, according to the final analysis of the PECATI phase 2 trial published on Friday.
This regimen offers a potential therapeutic option for advanced thymic carcinoma following platinum-based chemotherapy.
Clinical Insights for Thymic Tumor Management
- Targeted Combination: Lenvatinib and pembrolizumab are used together as a combination therapy in this setting.
- Survival Outcomes: In a cohort of 43 patients, the trial previously met its primary end point, with a 5-month progression-free survival rate of 88.0%, and the final analysis reports updated efficacy after longer follow-up.
- Toxicity Awareness: Nearly half of the participants experienced grade 3 or higher treatment-related adverse events, necessitating rigorous clinical oversight during the course of therapy.
Long-term Survival Analysis in the PECATI Trial
Investigators enrolled 43 patients with a median age of 57 years, the majority of whom—84%—presented with thymic carcinoma. These patients faced significant disease burdens, with 65% presenting at Masaoka-Koga stage IVB and 44.2% having already received two or more prior lines of therapy.
The trial previously met its primary end point, reporting an 88.0% progression-free survival rate at 5 months. The final analysis reports updated efficacy and safety after longer follow-up in a heavily pretreated population. However, the study remains a single-arm, phase 2 design, which limits the ability to compare these outcomes directly against other therapeutic standards or to isolate the specific contribution of either drug to the observed results.
Managing Treatment-Related Toxicity
While the investigators characterized the safety profile as manageable, they cautioned that close monitoring is needed. Investigators reported that 44.2% of patients experienced grade 3 or higher treatment-related adverse events (TRAEs). Furthermore, 27.9% of the study population found it necessary to discontinue at least one of the two study drugs due to toxicity.
Immune-related adverse events (irAEs) occurred in 39.5% of the cohort. Among the most concerning serious events reported were colitis, pneumonitis, myocarditis, encephalitis, and hepatotoxicity, with grade 3 immune-related events occurring in 11.6% of patients. Two grade 5 events—fatal outcomes—were documented; however, investigators concluded these were unrelated to the study treatment.
| Metric | Result |
|---|---|
| 5-Month Progression-Free Survival Rate | 88.0% |
| Patients with Grade 3+ TRAEs | 44.2% |
| Discontinuation Rate (≥1 Drug) | 27.9% |
| Grade 3 Immune-Related AEs | 11.6% |
New Combination Therapy May Treat Advanced B3 Thymoma
Currently, there is no standardized second-line treatment for advanced B3 thymoma or thymic carcinoma following failure of platinum-based chemotherapy. Remon, in a news release from the International Association for the Study of Lung Cancer, said that this combination may serve as a viable option for selected patients, provided that clinicians maintain strict monitoring for treatment-related toxicity.
Future investigations are already underway to determine the role of this combination in earlier treatment settings. The Artemis trial (NCT05832827), an investigator-initiated phase 2 study sponsored by the National Cancer Center in Japan, is currently evaluating the quadruple combination of carboplatin, paclitaxel, lenvatinib, and pembrolizumab as a first-line treatment for advanced or recurrent thymic carcinomas.
Researchers emphasize that further prospective studies are essential to identify which patients are most likely to benefit and to establish optimal treatment sequencing.